Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1/2 × Sarcoma × Immunoconjugates × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Sarcoma 1 Rectal Neoplasms 1 Prostatic Neoplasms 1 Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1

Interventions

Gemcitabine 15 pembrolizumab 13 Doxorubicin 13 Radiotherapy 12 Docetaxel 9 Nivolumab 8 Filgrastim 7 Cyclophosphamide 7 pazopanib 6 Ifosfamide 6 130-nm albumin-bound paclitaxel 5 Temozolomide 4 Irinotecan 4 Ipilimumab 4 Imatinib Mesylate 4 Albumin-Bound Paclitaxel 4 talimogene laherparepvec 3 surufatinib 3 pegfilgrastim 3 eribulin 3 atezolizumab 3 Vinorelbine 3 Sirolimus 3 Peripheral Blood Stem Cell Transplantation 3 PM 01183 3 Drug Therapy 3 Cisplatin 3 toripalimab 2 spartalizumab 2 selinexor 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06797999 2026-01-28

ADCElerate1

Adcendo ApS

Phase 1/2 Recruiting

Sarcoma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡